Recent News

• 12.08.2025 - Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
• 11.07.2025 - Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
• 11.06.2025 - Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
• 11.06.2025 - Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
• 10.30.2025 - Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
• 10.23.2025 - Coherus Oncology to Participate in Upcoming Investor Conferences
• 10.03.2025 - Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
• 10.03.2025 - Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
• 10.01.2025 - UBS Virtual Oncology Day Presentation
• 09.10.2025 - H.C. Wainwright 27th Annual Global Investment Conference Fireside Chat with Coherus Oncology

Recent Filings

• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - S-3 Registration statement under Securities Act of 1933
• 11.13.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 11.13.2025 - 8-K Current report
• 11.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.06.2025 - EX-99.1 EX-99.1
• 11.06.2025 - 8-K Current report
• 11.04.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 09.08.2025 - 8-K Current report